# Phase 2 Study of Rivaroxaban Reversal by Ciraparantag as Measured by WBCT

> **NCT03172910** · PHASE2 · COMPLETED · sponsor: **Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.** · enrollment: 69 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Ciraparantag
- **DRUG:** Placebo
- **DRUG:** Rivaroxaban

## Key facts

- **NCT ID:** NCT03172910
- **Lead sponsor:** Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-08
- **Primary completion:** 2019-11-12
- **Final completion:** 2019-11-12
- **Target enrollment:** 69 (ACTUAL)
- **Last updated:** 2025-09-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03172910

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03172910, "Phase 2 Study of Rivaroxaban Reversal by Ciraparantag as Measured by WBCT". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03172910. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*